Transgene

Transgene Interest Expense

The Interest Expense of Transgene (TNG.PA) as of Nov 18, 2026 is 462,000.00 EUR. In the previous year, Interest Expense was 213,000.00 EUR — a change of 116.90% (higher).

Interest Expense

462,000.00EUR

YoY

116.90%

Last updated:

Interest Expense of Transgene is 2024 462,000.00 EUR. Interest Expense of Transgene was 2023 213,000.00 EUR. It decreases by 116.90% higher compared to the previous year.

The Transgene Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2017
-2.93 M EUR
Jan 1, 2018
1.77 M EUR
Jan 1, 2019
-1.51 M EUR
Jan 1, 2020
-1.25 M EUR
Jan 1, 2021
-209,000.00 EUR
Jan 1, 2022
-381,000.00 EUR
Jan 1, 2023
213,000.00 EUR
Jan 1, 2024
462,000.00 EUR
The Transgene Interest Expense history
YEARInterest ExpenseYoY
462,000.00EUR+116.90%
213,000.00EUR-155.91%
-381,000.00EUR+82.30%
-209,000.00EUR-83.33%
-1.25 MEUR-17.06%
-1.51 MEUR-185.23%
1.77 MEUR-160.53%
-2.93 MEUR+84.11%
-1.59 MEUR+18.72%
-1.34 MEUR+61.18%
-832,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Interest Expense of Transgene is 462,000.00 EUR in 2024.

Interest Expense of Transgene changed from 213,000.00 EUR to 462,000.00 EUR, representing a 116.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Transgene since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Transgene

All Key Metrics — Transgene